NA Foot and Ankle Allograft Market - Industry Trends and Forecast to 2029

TABLE OF CONTENT

TABLE OF CONTENTS 1 INTRODUCTION 31 1.1 OBJECTIVES OF THE STUDY 31 1.2 MARKET DEFINITION 31 1.3 OVERVIEW OF NORTH AMERICA FOOT AND ANKLE ALLOGRAFTS MARKET 31 1.4 LIMITATIONS 33 1.5 MARKETS COVERED 33 2 MARKET SEGMENTATION 36 2.1 MARKETS COVERED 36 2.2 GEOGRAPHICAL SCOPE 37 2.3 YEARS CONSIDERED FOR THE STUDY 38 2.4 CURRENCY AND PRICING 38 2.5 DBMR TRIPOD DATA VALIDATION MODEL 39 2.6 MULTIVARIATE MODELLING 42 2.7 END USER LIFELINE CURVE 42 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 43 2.9 DBMR MARKET POSITION GRID 44 2.10 MARKET APPLICATION COVERAGE GRID 45 2.11 VENDOR SHARE ANALYSIS 46 2.12 SECONDARY SOURCES 47 2.13 ASSUMPTIONS 47 3 EXECUTIVE SUMMARY 48 4 PREMIUM INSIGHTS 50 4.1 PORTERS FIVE FORCES 51 5 INDUSTRIAL INSIGHTS: 52 5.1 CONCLUSION: 52 6 NORTH AMERICA FOOT AND ANKLE ALLOGRAFTS MARKET: REGULATIONS 53 6.1 U.S. 54 6.2 CANADA 55 6.3 EUROPE 55 7 MARKET OVERVIEW 57 7.1 DRIVERS 59 7.1.1 GROWING GERIATRIC POPULATION 59 7.1.2 INCREASE IN PREVALENCE OF MUSCULOSKELETAL DISORDER 59 7.1.3 INCREASE IN HEALTHCARE EXPENDITURE 60 7.1.4 INCREASE IN STRATEGIC INITIATIVES BY MAJOR MARKET PLAYERS 61 7.2 RESTRAINTS 62 7.2.1 STRINGENT REGULATORY 62 7.2.2 COMPLICATION AND RISK OF ALLOGRAFTS 62 7.3 OPPORTUNITIES 63 7.3.1 INCREASE IN NUMBER OF SPORTS INJURIES 63 7.3.2 RISE IN AWARENESS INITIATIVES ABOUT THE ALLOGRAFT PROCEDURE: 64 7.3.3 INCREASING RISK OF OSTEOPOROSIS AND OSTEOARTHRITIS: 65 7.4 CHALLENGES 66 7.4.1 COVID-19 IMPACT ON NORTH AMERICA FOOT AND ANKLE ALLOGRAFTS MARKET 66 7.4.2 ALLOGRAFT IS OFTEN CONSIDERED TOO EXPENSIVE IN LOW-INCOME TO MIDDLE-INCOME COUNTRIES: 67 7.4.3 HIGHER ADOPTION OF ALTERNATIVE THERAPIES FOR THE TREATMENT OF FOOT AND ANKLE DISORDERS: 68 8 NORTH AMERICA FOOT AND ANKLE ALLOGRAFTS MARKET, BY PRODUCT TYPE 69 8.1 OVERVIEW 70 8.2 ALLOGRAFT WEDGES 73 8.3 ALLOGRAFT TENDONS 73 8.4 ALLOGRAFT ACELLULAR DERMAL MATRIX 74 8.5 CARTILAGE ALLOGRAFT MATRIX 75 8.6 SKIN ALLOGRAFTS 76 8.7 AMNIOTIC MEMBRANES 77 9 NORTH AMERICA FOOT AND ANKLE ALLOGRAFTS MARKET, BY SURGERY TYPE 78 9.1 OVERVIEW 79 9.2 ORTHOPEDIC RECONSTRUCTION 82 9.2.1 NON-UNIONS FRACTURES 83 9.2.2 ARTHRODESIS PROCEDURES 83 9.2.3 OSTEOTOMY PROCEDURES 83 9.3 CARTILAGE RESTORATION 83 9.3.1 TALAR DOME REPAIR 84 9.3.2 TIBIAL PLAFOND REPAIR 84 9.3.3 METATARSAL REPAIR 84 9.3.4 TALONAVICULAR JOINT REPAIR 84 9.3.5 SUBTALAR JOINT REPAIR 84 9.4 SOFT TISSUE TENDON & LIGAMENT REPAIR 84 9.4.1 TENDON AUGMENTATION 85 9.4.2 LIGAMENT REPAIR 85 9.4.3 FAT PAD REPLACEMENT 85 9.4.4 PLANTAR PLATE REPAIR 86 9.5 WOUND CARE 86 9.5.1 ANKLE ULCER TREATMENT 87 9.5.2 NEUROPATHIC FOOT ULCER TREATMENT 87 10 NORTH AMERICA FOOT AND ANKLE ALLOGRAFTS MARKET, BY PROCEDURE 88 10.1 OVERVIEW 89 10.2 MIDFOOT PROCEDURES 92 10.2.1 CUBOID FRACTURE 93 10.2.2 FIRST TARSOMETATARSAL JOINT ARTHRODESIS 93 10.2.3 MEDIAL COLUMN ARTHRODESIS 93 10.2.4 LISFRANC 93 10.2.5 MEDIAL CUNEIFORM DORSAL OPENING WEDGE (COTTON) OSTEOTOMY 93 10.2.6 NAVICULAR CUNEIFORM ARTHRODESIS 93 10.2.7 NAVICULAR FRACTURE 93 10.2.8 OTHER MIDFOOT PROCEDURES 93 10.3 HIND-FOOT PROCEDURES 93 10.3.1 CALCANEAL FRACTURE 94 10.3.2 LATERAL COLUMN LENGTHENING 94 10.3.3 TALONAVICULAR JOINT ARTHRODESIS 95 10.3.4 TRIPLE ARTHRODESIS 95 10.3.5 OTHER HINDFOOT PROCEDURES 95 11 NORTH AMERICA FOOT AND ANKLE ALLOGRAFTS MARKET, BY END USER 96 11.1 OVERVIEW 97 11.2 HOSPITALS 100 11.3 ORTHOPEDIC CLINICS 100 11.4 AMBULATORY SURGICAL CENTERS 101 11.5 ACADEMIC AND RESEARCH INSTITUTES 102 11.6 OTHER END USERS 103 12 NORTH AMERICA FOOT AND ANKLE ALLOGRAFT MARKET, BY REGION 104 12.1 NORTH AMERICA 105 12.1.1 U.S. 113 12.1.2 CANADA 116 12.1.3 MEXICO 119 13 NORTH AMERICA FOOT AND ANKLE ALLOGRAFTS MARKET: COMPANY LANDSCAPE 122 13.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 122 14 SWOT ANALYSIS 123 15 COMPANY PROFILE 124 15.1 LIFENET HEALTH 124 15.1.1 COMPANY SNAPSHOT 124 15.1.2 COMPANY SHARE ANALYSIS 124 15.1.3 PRODUCT PORTFOLIO 125 15.1.4 RECENT DEVELOPMENTS 126 15.1.4.1 CONFERENCE 126 15.1.4.2 PRODUCT LAUNCH 127 15.2 ZIMMER BIOMET 128 15.2.1 COMPANY SNAPSHOT 128 15.2.2 REVENUE ANALYSIS 128 15.2.3 COMPANY SHARE ANALYSIS 129 15.2.4 PRODUCT PORTFOLIO 129 15.2.5 RECENT DEVELOPMENT 129 15.2.5.1 PARTNERSHIP 129 15.3 JOHNSON & JOHNSON SERVICES, INC. 130 15.3.1 COMPANY SNAPSHOT 130 15.3.2 REVENUE ANALYSIS 130 15.3.3 COMPANY SHARE ANALYSIS 131 15.3.4 PRODUCT PORTFOLIO 131 15.3.5 RECENT DEVELOPMENTS 131 15.3.5.1 EVENT 131 15.3.5.2 PRODUCT LAUNCH 131 15.4 INTEGRA LIFESCIENCES 132 15.4.1 COMPANY SNAPSHOT 132 15.4.2 REVENUE ANALYSIS 132 15.4.3 COMPANY SHARE ANALYSIS 133 15.4.4 PRODUCT PORTFOLIO 133 15.4.5 RECENT DEVELOPMENTS 133 15.4.5.1 POSITIVE CLINICAL OUTCOME 133 15.4.5.2 AGREEMENT 133 15.4.5.3 ACQUISITION 134 15.5 CONMED CORPORATION (2022) 135 15.5.1 COMPANY SNAPSHOT 135 15.5.2 REVENUE ANALYSIS 135 15.5.3 COMPANY SHARE ANALYSIS 136 15.5.4 PRODUCT PORTFOLIO 136 15.5.5 RECENT DEVELOPMENT 137 15.5.5.1 ACQUISITION 137 15.6 ALLOSOURCE 138 15.6.1 COMPANY SNAPSHOT 138 15.6.2 PRODUCT PORTFOLIO 138 15.6.3 RECENT DEVELOPMENT 139 15.6.3.1 PRODUCT LAUNCH 139 15.7 ALON SOURCE GROUP 140 15.7.1 COMPANY SNAPSHOT 140 15.7.2 PRODUCT PORTFOLIO 140 15.7.3 RECENT DEVELOPMENT 140 15.8 AMNIOX MEDICAL INC. 141 15.8.1 COMPANY SNAPSHOT 141 15.8.2 PRODUCT PORTFOLIO 141 15.8.3 RECENT DEVELOPMENT 141 15.8.3.1 PARTNERSHIP 141 15.9 ARTHREX 142 15.9.1 COMPANY SNAPSHOT 142 15.9.2 PRODUCT PORTFOLIO 142 15.9.3 RECENT DEVELOPMENT 142 15.9.3.1 PRODUCT LAUNCH 142 15.10 BIOVENTUS 143 15.10.1 COMPANY SNAPSHOT 143 15.10.2 REVENUE ANALYSIS 143 15.10.3 PRODUCT PORTFOLIO 144 15.10.4 RECENT DEVELOPMENT 144 15.10.4.1 CO-DEVELOPMENT 144 15.11 BONE BANK ALLOGRAFTS 145 15.11.1 COMPANY SNAPSHOT 145 15.11.2 PRODUCT PORTFOLIO 145 15.11.3 RECENT DEVELOPMENTS 145 15.11.3.1 PARTNERSHIP 145 15.12 GLOBUS MEDICAL 146 15.12.1 COMPANY SNAPSHOT 146 15.12.2 REVENUE ANALYSIS 146 15.12.3 PRODUCT PORTFOLIO 147 15.12.4 RECENT DEVELOPMENTS 147 15.12.4.1 M&A 147 15.13 INSTITUT STRAUMANN 148 15.13.1 COMPANY SNAPSHOT 148 15.13.2 REVENUE ANALYSIS 148 15.13.3 PRODUCT PORTFOLIO 149 15.13.4 RECENT DEVELOPMENT 149 15.14 JRF ORTHO 150 15.14.1 COMPANY SNAPSHOT 150 15.14.2 PRODUCT PORTFOLIO 150 15.14.3 RECENT DEVELOPMENT 151 15.14.3.1 PARTNERSHIP 151 15.15 NVISION BIOMEDICAL TECHNOLOGIES. 152 15.15.1 COMPANY SNAPSHOT 152 15.15.2 PRODUCT PORTFOLIO 152 15.15.3 RECENT DEVELOPMENT 152 15.15.3.1 ACQUISITION 152 15.16 PARAGON28, INC. 153 15.16.1 COMPANY SNAPSHOT 153 15.16.2 REVENUE ANALYSIS 153 15.16.3 PRODUCT PORTFOLIO 154 15.16.4 RECENT DEVELOPMENT 154 15.16.4.1 ACQUISITION 154 15.17 ORGANOGENESIS INC 155 15.17.1 COMPANY SNAPSHOT 155 15.17.2 REVENUE ANALYSIS 155 15.17.3 PRODUCT PORTFOLIO 156 15.17.4 RECENT DEVELOPMENTS 156 15.17.4.1 CONFERENCE 156 15.17.4.2 ACQUISITION 156 15.18 SMITH + NEPHEW 157 15.18.1 COMPANY SNAPSHOT 157 15.18.2 REVENUE ANALYSIS 157 15.18.3 PRODUCT PORTFOLIO 158 15.18.4 RECENT DEVELOPMENTS 158 15.18.4.1 EVENT 158 15.18.4.2 ACQUISITION 158 15.19 STRYKER 159 15.19.1 COMPANY SNAPSHOT 159 15.19.2 REVENUE ANALYSIS 159 15.19.3 PRODUCT PORTFOLIO 160 15.19.4 RECENT DEVELOPMENT 160 16 QUESTIONNAIRE 161 17 RELATED REPORTS 164